JP2015533085A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533085A5 JP2015533085A5 JP2015534880A JP2015534880A JP2015533085A5 JP 2015533085 A5 JP2015533085 A5 JP 2015533085A5 JP 2015534880 A JP2015534880 A JP 2015534880A JP 2015534880 A JP2015534880 A JP 2015534880A JP 2015533085 A5 JP2015533085 A5 JP 2015533085A5
- Authority
- JP
- Japan
- Prior art keywords
- bases
- seq
- oligonucleotide
- edema
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 21
- 206010030113 Oedema Diseases 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 230000008728 vascular permeability Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000037906 ischaemic injury Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000002847 Surgical Wound Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 238000011084 recovery Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102000008790 VE-cadherin Human genes 0.000 claims 2
- 108010018828 cadherin 5 Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000017423 tissue regeneration Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010061688 Barotrauma Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000019468 Iatrogenic Disease Diseases 0.000 claims 1
- 206010025282 Lymphoedema Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 241000973887 Takayama Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000003127 knee Anatomy 0.000 claims 1
- 238000011542 limb amputation Methods 0.000 claims 1
- 208000002502 lymphedema Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904297 | 2012-10-02 | ||
| AU2012904297A AU2012904297A0 (en) | 2012-10-02 | Modulation of RNA activity and vascular permeability | |
| AU2012904365A AU2012904365A0 (en) | 2012-10-05 | Modulation of RNA activity and vascular permeability | |
| AU2012904365 | 2012-10-05 | ||
| PCT/AU2013/001129 WO2014053014A1 (en) | 2012-10-02 | 2013-10-02 | Modulation of rna activity and vascular permeability |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533085A JP2015533085A (ja) | 2015-11-19 |
| JP2015533085A5 true JP2015533085A5 (enExample) | 2018-02-22 |
| JP6430945B2 JP6430945B2 (ja) | 2018-11-28 |
Family
ID=50434322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534880A Active JP6430945B2 (ja) | 2012-10-02 | 2013-10-02 | Ｒｎａ活性及び血管透過性の調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9879255B2 (enExample) |
| EP (1) | EP2904102B1 (enExample) |
| JP (1) | JP6430945B2 (enExample) |
| CN (1) | CN104995300B (enExample) |
| AU (1) | AU2013327393B2 (enExample) |
| CA (1) | CA2886745A1 (enExample) |
| WO (1) | WO2014053014A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879255B2 (en) | 2012-10-02 | 2018-01-30 | University Of Newcastle Upon Tyne | Modulation of RNA activity and vascular permeability |
| EP3331535A4 (en) * | 2015-08-05 | 2019-03-13 | Centenary Institute Of Cancer Medicine And Cell Biology | METHOD FOR TREATING TUMORS |
| CN105861728B (zh) * | 2016-06-12 | 2024-11-19 | 上海市第十人民医院 | 循环miRNA作为年龄相关黄斑变性诊断标志物中的应用 |
| WO2025102119A1 (en) * | 2023-11-16 | 2025-05-22 | Centenary Institute Of Cancer Medicine And Cell Biology | Improvement of blood brain barrier integrity |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000103736A (ja) * | 1998-07-31 | 2000-04-11 | Takeda Chem Ind Ltd | 血管透過性亢進抑制剤 |
| JP2000143536A (ja) * | 1998-11-13 | 2000-05-23 | Nippon Zoki Pharmaceut Co Ltd | 抗浮腫剤 |
| US20050014172A1 (en) * | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
| EP1900374B1 (en) * | 2005-06-16 | 2014-03-12 | Takayuki Shindo | Angiogenetic agent containing adrenomedulin as the active ingredient |
| AU2014250708B2 (en) | 2006-11-23 | 2016-11-10 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| AU2007323469B2 (en) | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| CN101641440A (zh) * | 2006-11-23 | 2010-02-03 | 米尔克斯治疗有限责任公司 | 用于调节靶rna活性的寡核苷酸 |
| CA2690643A1 (en) | 2007-06-14 | 2008-12-18 | Mirx Therapeutics Aps | Oligonucleotides for modulation of target rna activity |
| WO2010139026A1 (en) | 2009-06-05 | 2010-12-09 | Centenary Institute Of Cancer Medicine And Cell Biology | Therapeutic and diagnostic molecules |
| SG2014008171A (en) * | 2009-06-22 | 2014-04-28 | Ampio Pharmaceuticals Inc | Method for treatment of diseases |
| WO2011117353A1 (en) | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
| US9145557B2 (en) | 2010-11-23 | 2015-09-29 | Mirrx Therapeutics A/S | Oligonucleotides for modulation of target RNA activity |
| CN104955950B (zh) | 2012-09-26 | 2019-04-26 | 米尔克斯治疗学公司 | 具有改善的脱靶特征谱的寡核苷酸 |
| US9879255B2 (en) | 2012-10-02 | 2018-01-30 | University Of Newcastle Upon Tyne | Modulation of RNA activity and vascular permeability |
| CN104902901A (zh) | 2012-10-19 | 2015-09-09 | 株式会社棱镜制药 | 使用cbp/连环蛋白的抑制剂治疗过度增殖性和癌前皮肤病 |
-
2013
- 2013-10-02 US US14/433,150 patent/US9879255B2/en active Active
- 2013-10-02 EP EP13843154.9A patent/EP2904102B1/en active Active
- 2013-10-02 WO PCT/AU2013/001129 patent/WO2014053014A1/en not_active Ceased
- 2013-10-02 CA CA2886745A patent/CA2886745A1/en not_active Abandoned
- 2013-10-02 CN CN201380061417.2A patent/CN104995300B/zh active Active
- 2013-10-02 JP JP2015534880A patent/JP6430945B2/ja active Active
- 2013-10-02 AU AU2013327393A patent/AU2013327393B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531036A5 (enExample) | ||
| JP2019517464A5 (enExample) | ||
| RU2013120312A (ru) | Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов | |
| WO2010137900A3 (ko) | 선택적 경색 조직 타겟팅 박테리아 및 그의 용도 | |
| Jung | Recent advances in management of gout | |
| GB201212111D0 (en) | Vascular bed-specific endothelial cells | |
| CN108310017A (zh) | Let-7i的抑制剂在制备治疗心肌缺血损伤的药物中的应用 | |
| KS | A comparative study of volar locking plate versus external fixation for displaced intra articular distal end radius fractures: A prospective study | |
| WX et al. | DYNAMIC OBSERVATION OF VASCULAR REGENERATION IN FEMORAL HEAD NECROSIS: A 5-YEAR FOLLOW-UP CASE REPORT | |
| Корольков et al. | Characteristics of stress-strain foot model before and after subtalar arthroereisis with implants at the treatment of flatfoot (message 2) | |
| Ghafari et al. | Correction to: Prevalence of HIV-1 transmitted drug resistance in recently infected, treatment-naïve persons in the Southwest of Iran, 2014-2015 | |
| Bobrova et al. | The method of primary surgical treatment of the penetrating cornea injuries | |
| Rogers et al. | The Potential of Gene Therapy in Podiatric Medicine. | |
| Tamburino et al. | Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease. | |
| of Chinese et al. | Top ten progressions of clinical research in fundus diseases in China | |
| Bobrova et al. | A LONG-TERM RESULTS OF FULL-THICKNESS SUTURE METHOD OF PRIMARY SURGICAL TREATMENT OF PENETRATING CORNEAL WOUND | |
| Pankratova et al. | Specificities of Clinical Manifestations of Generalized Tuberculosis in Contemporary Conditions | |
| Datskih et al. | Clinico-statistical analysis of the volume and types of surgical treatment of cataract and glaucoma in the past 10 years | |
| Nusinovich | Interfering with diabetes | |
| Otamuradov | Rectovestibular fistula with normal anus | |
| Bredikhin et al. | Diagnosis and treatment of varicose disease of small pelvic veins | |
| МАҲМАДОВ | HEALTH ACTIVITIES IN KULYAB REGION DURING THE GREAT PATRIOTIC WAR IN 1941-1945 | |
| Feigin et al. | THE VARIANTS OF APPROACH FOR REMOVAL EXTENSIVE TUMORS OF MAXILA-FACIAL REGION | |
| SUDHAKAR et al. | BITE-SIZED REVIEW ON ADVANCE DELIVERY SYSTEM, SUPPORT IN THE MANAGEMENT OF COVID-19 | |
| Bareš et al. | Treatment-resistant depression II: Basic principles and strategies of treatment |